Migraine, idiopathic intracranial hypertension, and calcitonin gene-related peptide antibodies
- PMID: 38477415
- DOI: 10.1111/head.14686
Migraine, idiopathic intracranial hypertension, and calcitonin gene-related peptide antibodies
Comment on
-
Idiopathic intracranial hypertension presenting with migraine phenotype is associated with unfavorable headache outcomes.Headache. 2023 May;63(5):601-610. doi: 10.1111/head.14478. Epub 2023 Feb 8. Headache. 2023. PMID: 36753388
References
REFERENCES
-
- Bsteh G, Macher S, Krajnc N, et al. Idiopathic intracranial hypertension presenting with migraine phenotype is associated with unfavorable headache outcomes. Headache. 2023;63(5):601-610. doi:10.1111/head.14478
-
- Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology. 2013;81(13):1159-1165. doi:10.1212/WNL.0b013e3182a55f17
-
- Yiangou A, Mitchell JL, Vijay V, et al. Calcitonin gene related peptide monoclonal antibody treats headache in patients with active idiopathic intracranial hypertension. J Headache Pain. 2020;21(1):116.
-
- Frerichs L, Nandy K, Friedman DI. Effectiveness of anti-CGRP monoclonal antibodies for persistent headaches in patients with idiopathic intracranial hypertension. Headache. 2022;62(supp 1):119.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
